Zai Lab Reports Q3 2026 Financial Results and Clinical Progress
Zai Lab (ZLAB) reported third-quarter 2026 total revenue of $108.2 million, a decrease from $116.1 million in the same period last year. Despite the decline in top-line revenue, net product revenue saw a 2% sequential increase from Q2 2026. The company reported a net loss per ADS of $0.41, compared to $0.33 in the prior year, impacted by inventory write-downs and increased R&D spending. On the clinical front, Zai Lab highlighted strong efficacy data for its Zoci candidate in first-line small cell lung cancer (SCLC), showing an 81.8% objective response rate. The company also noted successful results from the VYVGART ALKIVIA study and progress in its DLLEVATE and epNEC programs, both of which are targeting potential U.S. accelerated approvals in 2027. To bolster liquidity, Zai Lab completed a $250 million private placement in October.
Tickers: $ZLAB
Topics: cash position clinical trial results private placement R&D expenses revenue